Kornimate/medical-research-clean huggingface dataset:
change in gingival volume and quality of life due to initial periodontal therapy in smokers

Conditions: Periodontitis

Summary: the aim of this study is to compare the dimensional changes of the gingiva due to initial periodontal therapy in non-smokers and cigarette smokers and to compare the oral health related quality of life of non-smokers and cigarette smokers with periodontitis before and after initial periodontal therapy. changes in gingival volume are expected to be greater in non-smokers than in cigarette smokers. it is expected that the quality of life will be better after therapy in both groups, with better results in the non-smoking group. 60 subjects with periodontitis will be included in the study 30 non-smokers and 30 cigarette smokers. all subjects will fill out a quality of life questionnaire which will be validated before the onset of this research. this will be followed by clinical periodontal examination. after examination, the upper and lower jaw will be scanned using an intraoral scanner and initial periodontal therapy will be performed. after 8 weeks, subjects will fill out the quality of life questionnaire again, measurement of periodontal indices and scanning will be performed. the digital scans wll be superimposed, and the dimensional changes of the gingiva will be quantified and compared between the two groups. by using 3d technology, it will be possible to objectively quantify tissue changes and monitor the course of the disease. a 3d comparison between non-smokers and cigarette smokers will provide a new perspective on the relationship between smoking and periodontitis. furthermore, it will be demonstrated to what extent smoking affects the quality of life of patients with periodontitis and the results of non-surgical therapy.


Eligibility criteria:
inclusion criteria: * periodontitis * cigarette smokers * non smokers exclusion criteria: * previous periodontal treatment * pregnancy * minors * antibiotic therapy in the last 6 months * patients with ortho appliances * patients using drugs that affect gingival volume * immunosuppressive therapy * systemic conditions that affects periodontal tissues and therapy

Keywords: 3d imaging gingiva nonsurgical periodontal debridement periodontitis quality of life smoking
discrimination harassment of pain staff caused by patient

Conditions: Abuse, Sexual; Abuse, Workplace

Summary: chronic pain is associated with mental disorders, and some patients have behavioral issues. some patients may sexually or racially harass pain clinic staff. healthcare staff do not usually report sexual or racial harassment perpetrated by patients. quantitative and qualitative analysis of prospective electronic and clinic diary data. evaluation of incidents of sexual and racial harassment of clinic staff; perpetrated by patients. analysis of causative factors, incident outcome, system factors and lessons learned.

chronic pain disorder may be associated with mental health disease. many patients exhibit behavioral problems. some of the patients may sexually or racially harass the pain clinic staff. typically, healthcare providers do not report racial or sexual harassment perpetrated by patients. this is a quantitative analysis of prospective electronic and clinic diary data. it evaluates many incidents of sexual and racial harassment of pain clinic staff; perpetrated by patients. it analyzes the incident causative factors, incident outcomes, system factors and lessons learned. the qualitative information of each incident is presented in a sensitive and careful format.

Eligibility criteria:
inclusion criteria: * adult chronic pain patients exclusion criteria: * pediatric chronic pain patients

Keywords: harassment by patients
treatment of adults with growth hormone deficiency

Conditions: Pituitary Disorders; Adult Growth Hormone Deficiency

Summary: the purpose of this study is to evaluate efficacy and safety profile of a new weekly administered growth hormone preparation compared with placebo in adults with growth hormone deficiency.


Eligibility criteria:
inclusion criteria: * male or female of at least 23 years and not more than 70 years of age * ghd of either adult onset(ao)or childhood onset(co), either idiopathic or secondary to pituitary disease * confirmed diagnosis of ghd defined * igf-1 sds ≤ -1 at screening * no exposure to rhgh within the last 6 months * patients with adequate adrenal function, which is confirmed by acth stimulation test at screening; or patients with known secondary hypoadrenalism on adequate glucocorticoid replacement therapy * if applicable, hormone replacement therapies for any other hormone deficiencies, adequate and stable for at least 3 months before study entry * women of child-bearing potential to be using a reliable method of contraception at the screening and be willing to use it throughout the study * a negative serum pregnancy test is required at screening for females of child-bearing potential. exclusion criteria: * history of malignancy other than cranial tumor or leukemia causing ghd or fully treated basal cell carcinoma * evidence of active malignancy * evidence of growth of pituitary adenoma or other intracranial tumor within the last 12 months, or patients without mri or ct data to confirm the tumor stability within the last 12 months * significant hepatic dysfunction * chronic renal impairment * clinically significant pulmonary, cardiac, hepatic, renal, or neuromuscular disease * prader-willi syndrome * acute severe illness in the last 6 months * benign intracranial hypertension * active cushing's syndrome within the last 12 months * uncontrolled hypertension * patients with overt diabetes mellitus or evidence of persistent impaired glucose tolerance * severe psychiatric disease or patients who cannot understand the objective and methods of the study or patients with current alcohol abuse * pregnancy or lactation * known hypersensitivity to any ingredient of the study drug * inability to undergo scanning by dual-energy x ray absorptiometry (dxa) due to a body weight more than 130 kg or in situ internal or external devices known to interfere with dxa scanning * weight reducing drugs or appetite suppressants * anabolic steroids other than gonadal steroid replacement therapy within 2 months before study entry * methylphenidate within 2 months before study entry * systemic corticosteroids other than in replacement doses within the 3 months before study entry. * history of non-compliance with medications, un-cooperativeness or drug abuse * patients participating in another study parallel to, or within 6 months prior to study entry, or previous participation in this study * patients who are not able to comply with the study protocol for any reason.

Keywords: growth hormone deficiency
impact of prewarming on perioperative body core temperature and the outcomes of cytoreductive- and major open abdominal surgery: a randomised trial

Conditions: Hypothermia

Summary: the primary purpose of this study is to determine whether a prewarming period of at least 30 minutes during induction of general and combined epidural anesthesia reduces the core temperature drop normally occuring in patients undergoing cyto-reductive and major abdominal surgery. in addition the effect of prewarming on intra and postoperative body core temperature will be evaluated.


Eligibility criteria:
inclusion criteria: * age \> 18 * elective cytoreductive or major abdominal surgery caused by ovarian cancer, primarily or secondary exclusion criteria: * age \< 18 * refusal participate in study * pregnant or breast-feeding women * cardiac ejection fraction \< 30% * terminal renal insufficiency requiring dialysis * severe pulmonary disease (gina-classification\< 3) * neurological and/or psychiatric disease * patient is placed in an institution due to court order * lack of language skills/understanding * employee of charité berlin * alcohol addiction * refusal of epidural anesthesia or failure to insert epidural catheter * participation in other perioperative, invasive studies which prohibit further study inclusion

Keywords: prewarming perioperative hypothermia microdialysis tissue oxygen saturation cytoreductive surgery
visual restoration for hemianopia

Conditions: Stroke Induced Vision Loss; Hemianopia; Quadrantanopia

Summary: the purpose of this research is to assess the efficacy of a visual training task on reducing the size of a visual field deficit caused by brain damage in adults, and its ability to improve visual functions in this patient population.


Eligibility criteria:
inclusion criteria: * ages 21-75 years old * ability and willingness to sign informed consent * willingness to participate in both the training and evaluation sessions * mri or ct scan demonstrating lesion in the occipital lobe of the brain and/or affecting white matter tracts that provide visual input to the occipital lobe of the brain * brain injury due to ischemic or hemorrhagic causes that occurs after age 18 and at least 90 days prior to screening visit * at least two reliable hvf's demonstrating good fixation and a stable homonymous incomplete (e.g., quadrantanopia or relative defect) or complete hemianopia * reliable hvfs with repeat hvfs if randomization takes place more than 4 weeks after screening visit * a homonymous, contiguous visual deficit measured by the 24-2 hvf to be a minimum of two testing locations high and two testing locations wide, where impaired locations are any that measure a threshold of less than 15 db. * demonstration of good fixation on visual training task - able to fixate the small targets presented as fixation letters reliably for 1000ms with jitter over less than 1 degree of visual angle in any direction away from target edge exclusion criteria: * physical, neurological or mental disability that would interfere with study intervention * concurrent participation in "vision therapy" other than standard occupational or physical therapy * unreliable visual fields on prior testing, indicated by greater than 20% fixation losses, false positives, or false negatives. * inability to discontinue medications judged to affect training and/or assessment (e.g., ritalin, amphetamines, dopamines, or chemotherapeutic agents) * physical condition likely to preclude completion of the clinical trial (e.g. end-stage or uncontrolled cancer, uncontrolled epilepsy, or end-stage heart disease) * ocular or neurological condition that would interfere with training or assessment (e.g. damage to the optic nerves or lateral geniculate nucleus, any degenerative ocular condition) * best corrected vision worse than 20/40 * impaired foveal humphrey sensitivity as indicated by the hvf tests. * presence of vision loss resulting from ocular disease or disorder * presence of bilateral visual acuity loss from any source * inability to demonstrate fixation stability on eye movement monitored testing * inability to follow training instructions
the burden of lyme disease (bold) in a pandemic - insights from an online cross-sectional and prospective cohort survey

Conditions: COVID-19; Lyme Disease; COVID-19 Vaccine

Summary: a cross-sectional descriptive survey of the bold for individuals after having been ill with covid-19 or have taken the covid-19 vaccine will be compared with that of individuals who have neither been ill with covid-19 nor taken the covid-19 vaccine. individuals who have both been ill and taken the covid-19 vaccine will be compared to identify any additive risk factors.

primary research question: 1. will the bold be worse for individuals who have taken the covid-19 vaccine? secondary research questions: 1. will the bold be worse for individuals who have been ill with covid-19? 2. what factors affect the bold in individuals a) after having been ill with covid-19, and b) in those who have taken the covid-19 vaccine? do they differ? 3. if bold risk factors specific to either the covid-19 vaccine or having been ill with covid-19 are found, are they additive in people who have experienced both? 4. what is the prevalence of hesitancy in the lyme disease community to the covid-19 vaccine? 5. what is the severity of symptoms most likely to predict functional problems in individuals with lyme disease who have been ill with covid-19 or taken the covid-19 vaccine?

Eligibility criteria:
inclusion criteria: * ≥12 years old * a self-report of having been diagnosed with lyme disease. exclusion criteria: * there are no exclusion criteria.
shifting away from pain: a neurocognitive approach in treatment of whiplash

Conditions: Whiplash Injuries

Summary: the broad aim of this study is to investigate the effect of a modern neuroscience approach, which combines education on pain neuroscience with cognition-targeted exercise therapy and stress management, on brain structure and networks in patients with chronic whiplash-associated disorders (cwad) in comparison to a control physiotherapy treatment.

this project runs in parallel to a larger randomized-controlled trial (rct) in which the 'modern neuroscience approach to wad' is compared to usual care evidence-based physiotherapy (clinical trial registration number: nct03239938). for the current study, additional magnetic resonance imaging (mri) measures will be taken in a subsample of patients, who will be recruited from this larger rct. in addition, a pain-free age- and sex-matched control group will be recruited for comparison. the current study consists of 2 mri measurements that will take place at the university hospital of ghent (uz gent): baseline (pre-treatment) and follow-up (post-treatment; approximately 16 weeks after baseline). after pre-treatment assessment, the patients will be randomly allocated to the modern neuroscience approach or usual care physiotherapy, as part of the rct.

Eligibility criteria:
cwad group: inclusion criteria: * experienced a whiplash trauma which is at least 3 months old and causes pain since at least 3 months, with pain experience with a mean pain frequency of 3 or more days per week, and with self-reported moderate to severe pain-related disability, established by a score of 15 or more of a maximum of 50 on the neck disability index * patients classified as wad ii or wad iii on the modified quebec task force scale * native dutch speaker * not starting new treatments or medication and continuing their usual care 6 weeks prior to and during study participation (to obtain a steady state) * refraining from consuming caffeine, alcohol and nicotine in the hour before the mri scans (in both measurement times: before the start of the rehabilitation and after the end of the rehabilitation). exclusion criteria: * neuropathic pain * being pregnant or having given birth in the preceding year * chronic fatigue syndrome * fibromyalgia * cardiovascular disorders * epilepsy * endocrinological disorders * rheumatic disorders * psychiatric disorders * history of neck surgery * loss of consciousness during/after the whiplash trauma * mri incompatible health condition (e.g., pacemaker, metal prosthetic devices) * psychiatric condition and ongoing medication that would alter emotional or sensory processing * claustrophobia. healthy volunteers: (matched for age and gender). additional exclusion criteria include for healthy volunteers * a history of a chronic pain syndrome * a pain condition in the last six months for which treatment was sought
predicting physical activity change: an epidemiologic study

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to conduct a two-year follow up of participants in a cross-sectional study of physical activity determinants. predictors of change in vigorous exercise habits and recreational walking habits were identified as were determinants of change in the proportion of the sample who initiated, maintained, or discontinued exercise.

background: in 1988 when the study began, epidemiological studies had shown the health benefits of physical activity and that prevalence of physical activity was well below recommended levels. exercise-promotion interventions were typically ineffective, and lack of knowledge of exercise determinants inhibited the design of effective interventions. design narrative: data from the san diego health and exercise baseline survey conducted in 1986 were used to contact participants for the follow-up. the difference in reported activity level from time 1 to time 2 served as an estimate of change in activity. the follow-up survey elicited a two-year history of vigorous exercise and moderate-intensity exercise, both of which have substantial health benefits, as well as different determinants. potential predictors were assessed at baseline and included demographic variables and indices based on social learning theory. multiple regression analyses determine the combined and independent relationships of such variables as self-efficacy, social support, perceived barriers and benefits and environmental factors on both types of physical activity change. a second analysis separated subjects into the baseline physical activity groups of low, intermediate, and high activity and examined prediction of change versus no-change in each category.

Eligibility criteria:
inclusion 1. healthy adults 18-60 exclusion 2. cardiovascular disease 3. heart disease
prism adaptation training for treatment of spatial neglect during inpatient rehabilitation

Conditions: Stroke

Summary: left sided spatial neglect is a common yet potentially debilitating phenomena associated with right hemisphere stroke. heilman defines neglect as "the failure to report, respond, or orient to novel or meaningful stimuli presented to the side opposite of a brain lesion that cannot be attributed to either sensory or motor deficits". numerous studies have demonstrated the impact of spatial neglect in right hemisphere stroke patients on both rehabilitation outcomes, and subsequent functioning in the community. given the highly significant negative impact of spatial neglect, numerous treatment approaches have been attempted, yet most lack evidence in terms of efficacy. one promising exception has been prism adaptation training (pat), which several recent reviews reported improved independence as a benefit of this treatment, both in terms of ameliorating the severity of neglect and demonstrating generalization to important functional behaviors. still, much remains unknown regarding pat, and not all studies have shown positive results. at sunnyview rehabilitation hospital, a number of providers have added pat to the standard pt, ot and speech that stroke patients receive during their inpatient stay. as part of a process improvement initiative the investigators identified 57 patients that received pat training between june 2016 and september of 2019. the investigators propose a retrospective case-control study examining the impact of pat treatment on the rehabilitation outcomes for these patients. outcome variables to be assessed include the measures of spatial neglect (catherine bergego scale), functional independence measures (fim), length of hospitalization and discharge destination. the investigators hypothesize that patients who received 4 or more pat sessions during their inpatient rehabilitation stay will show improvements both in measures of neglect and functional independence as a result of this treatment.


Eligibility criteria:
inclusion criteria: * right hemisphere stroke * admitted between 6/2016 \& 12/2019 exclusion criteria: * absence of neglect * incomplete catherine bergego scale (less than 7 items scored) * evidence of traumatic brain injury * brain cancer * dementia * parkinson's disease * alzheimer's disease * aphasia * interrupted hospital admission
intraoperative adverse events in robotic radical gastrectomy for gastric cancer

Conditions: Gastric Cancer

Summary: surgical quality control is a crucial determinant of evaluating the tumor efficacy. we assess the classintra grade for quality control and oncological outcomes of robotic radical surgery for gastric cancer (gc).

gastric cancer (gc) is the fifth most common malignant tumor worldwide and the fourth leading cause of cancer-related deaths. surgery remains the cornerstone of gc treatment, and there is a significant lack of research on iae compared with postoperative complications. owing to the influence of reporting and cultural acceptance, there have been issues of inadequate reporting and non-standardized practices regarding iae reporting. the previously reported laparoscopic results showed that the classintra grade is an effective prognostic and surgical quality control index for laparoscopic radical surgery for gastric cancer therefore it could be included in routine hospital care and surgical quality control. (doi: 10.1097/sla.0000000000005727). here, iaes in patients who underwent robotic radical gastrectomy significantly correlated with the occurrence of postoperative complications and a poor long-term prognosis. therefore, utilization and inclusion of classintra grading as a crucial surgical quality control and prognostic indicator in the routine surgical quality evaluation system are recommended.

Eligibility criteria:
inclusion criteria: * patients diagnosed with gastric adenocarcinoma through pathology; * preoperative chest radiograph, abdominal ultrasonogram, and full abdominal ct examination showed no distant metastasis to the liver, lungs, or abdominal cavity; * patients who underwent robotic radical gastrectomy. exclusion criteria: * intraoperatively existing distant metastases * neoadjuvant chemotherapy * missing general and video data.

Keywords: gastric cancer
multicenter postmarket surveillance registry evaluating performance and long term safety of the presillion stent

Conditions: Coronary Arteriosclerosis

Summary: the purpose of this study is: to evaluate the safety and performance of the presillion stent in routine clinical practice.

primary endpoint: composite of major adverse cardiac events (mace), which includes cardiac death, myocardial infarction (q-wave and non q-wave) and clinically driven target lesion revascularization (tlr) at 12 months follow-up. data will be collected on 400 patients (from 14 hospitals in spain and portugal) treated with the presillion stent in up to 2 de novo native coronary artery lesions study design: multicenter, prospective, observational

Eligibility criteria:
inclusion criteria: * all subjects treated with presillion stent up to two de novo coronary artery lesions exclusion criteria: * no specified